Aike Baifa (爱科百发) sells just‑approved ADHD drug for cash — pivots back to respiratory bets. What are its chances?

Crown jewel cut loose as cash runs dry

Aike Baifa (爱科百发) has traded a potential breakout asset for breathing room. Its ADHD drug Aizhida (爱智达, AK0901) won China’s NMPA approval at the end of 2025 as the country’s first novel compound combining immediate‑ and extended‑release stimulants — a product touted to break import dependence in a fast‑growing ADHD market. But reportedly, just three months after approval the company ceded exclusive mainland commercialization rights to Qilu Pharmaceutical (齐鲁制药), reportedly in exchange for up to RMB 470 million in milestone payments plus royalties. Why sell the crown jewel so soon? The short answer: survival.

A five‑year IPO slog and a shrinking cash pile

Founded in 2014 by former Roche (罗氏) executive Wu Zheng (邬征), Aike Baifa has pursued an aggressive R&D path while repeatedly seeking a public listing — three separate filings for Hong Kong plus a stalled STAR Market attempt. It has burned through more than RMB 1 billion in cumulative net losses over six years, with R&D spend near RMB 975 million and year‑end cash reportedly down to around RMB 39 million. The company’s core pipelines include licensed assets originally brought in from foreign partners, meaning future royalty obligations and limited in‑house commercial muscle — a weakness exposed when immediate marketing scale is required.

Aizhida: big medical promise, limited corporate upside

Aizhida addresses a real domestic gap: China’s diagnosed ADHD population is rising and current drug supply has been import‑heavy and unstable. Market forecasts suggest the ADHD segment could expand from roughly RMB 1.1 billion (2024) toward a much larger opportunity as diagnosis rates climb. But Aike Baifa paid around US$105.5 million to acquire the asset in 2021 and then shouldered additional clinical and registration costs — yet will now forfeit much of the upside to Qilu’s commercial engine. It has been reported that the deal buys immediate cash and reduces marketing burn, but it also means Aike likely loses out on the fuller revenue stream as the market scales.

Doubling down on RSV and IPF — a high‑risk, capital‑intensive bet

With ADHD commercialization outsourced, Aike is effectively all‑in on respiratory disease — notably AK0529 (齐瑞索韦), an oral RSV therapeutic that has reached a listing application phase, and AK3280 for idiopathic pulmonary fibrosis. But the RSV landscape is shifting: early vaccine launches by GSK and Pfizer showed large initial sales followed by sharp pullbacks, and vaccine approvals in China are advancing — a development that could compress demand for therapeutic drugs. In short, Aike’s “断臂求生” may buy runway, but it leaves the company hinging its future on a narrow, volatile corner of the pharmaceutical market while exposing its limited commercialization capacity.